EcoDrugPlus

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSCAFG00020016170
Gene Symbol: CXCR4
3 Cross references
218 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSCAFG00020007486
Gene Symbol: CFTR
3 Cross references
217 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSCAFG00020023719
Gene Symbol: DNMT1
3 Cross references
212 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSCAFG00020012816
Gene Symbol: TOP1
3 Cross references
273 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSCAFG00020018681
Gene Symbol: TOP2A
3 Cross references
206 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSCAFG00020024760
Gene Symbol: TOP2B
3 Cross references
210 Possible Orthologues:

Dna-(Apurinic Or Apyrimidinic Site) Lyase-Like

Ensembl ID : ENSCAFG00020023002
Gene Symbol: LOC112664545
2 Cross references
213 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSCAFG00020021432
Gene Symbol: EML4
3 Cross references
214 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSCAFG00020004936
Gene Symbol: EPHA2
3 Cross references
124 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSCAFG00020009975
Gene Symbol: EPHA3
3 Cross references
216 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSCAFG00020013816
Gene Symbol: EPHB4
3 Cross references
168 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSCAFG00020010307
Gene Symbol: F2RL3
3 Cross references
193 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).